Evidence map›Paper›PMID 33667465›Full record

ArticleJournal of lipid research2021

Association of serum HDL-cholesterol and apolipoprotein A1 levels with risk of severe SARS-CoV-2 infection.

James R Hilser, Yi Han, Subarna Biswas, Janet Gukasyan, Zhiheng Cai, Ruowei Zhu, W H Wilson Tang, Arjun Deb, Aldons J Lusis, Jaana A Hartiala and 1 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of lipid research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 4 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 4 syntheses or guidelines pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Alterations in plasma proteome during acute COVID-19 and recovery.Molecular medicine (Cambridge, Mass.) · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

James R HilserDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA, USA; Department of Biochemistry and Molecular Medicine, University of Southern California, Los Angeles, CA, USA.
Yi HanDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA, USA; Department of Biochemistry and Molecular Medicine, University of Southern California, Los Angeles, CA, USA.
Subarna BiswasDepartment of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Janet GukasyanDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA, USA; Department of Biochemistry and Molecular Medicine, University of Southern California, Los Angeles, CA, USA.
Zhiheng CaiDepartment of Biochemistry and Molecular Medicine, University of Southern California, Los Angeles, CA, USA.
Ruowei ZhuDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA, USA; Department of Biochemistry and Molecular Medicine, University of Southern California, Los Angeles, CA, USA.
W H Wilson TangDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland OH, USA; Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland OH, USA.
Arjun DebDepartment of Medicine, David Geffen School of Medicine of UCLA, Los Angeles, CA, USA.
Aldons J LusisDepartment of Medicine, David Geffen School of Medicine of UCLA, Los Angeles, CA, USA; Department of Human Genetics, David Geffen School of Medicine of UCLA, Los Angeles, CA, USA; Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine of UCLA, Los Angeles, CA, USA.
Jaana A HartialaDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA, USA.
Hooman AllayeeDepartment of Preventive Medicine, University of Southern California, Los Angeles, CA, USA; Department of Biochemistry and Molecular Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: hallayee@usc.edu.
University of Southern California · USUniversity of California, Los Angeles · USCleveland Clinic · US

Funding

Metabolic and epigenetic reprogramming of vital organs in SARS-CoV-2 induced systemic toxicityR01DK132735 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARUMUGASWAMI, VAITHILINGARAJA, DEB, ARJUN · 2021 to 2023
$6.0M
Systems Genetics Dissection of Non-alcoholic SteatohepatitisR01DK117850 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Aldons Jake Lusis · 2019 to 2026
$4.6M
Role of Glycine Metabolism in Cardiovascular DiseaseR01HL133169 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ALLAYEE, HOOMAN · 2017 to 2020
$3.3M
Genetic and Environmental Determinants of Asthma EndophenotypesR01ES025786 · NIEHS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI AKBARI, OMID, ALLAYEE, HOOMAN · 2015 to 2019
$2.8M
Role of GPNMB in cardiac remodelingR01HL152176 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEB, ARJUN · 2021 to 2024
$2.8M
Gut microbiota and metabolite interactions in atherosclerosisR01HL144651 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LUSIS, ALDONS JAKE, REY, FEDERICO E · 2019 to 2022
$2.6M
Biological Mechanisms through which TMAO Promotes AtherosclerosisR01HL148110 · NHLBI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ALLAYEE, HOOMAN, SHIH, DIANA MOUHAN · 2020 to 2023
$2.5M
Targeting cardiac fibroblast-myocyte cross talk to enhance heart function after cardiac injuryR01HL149658 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEB, ARJUN · 2020 to 2023
$2.2M
Role of ABCC6 in cardivascular calcificationR01HL137241 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEB, ARJUN · 2017 to 2020
$2.1M
Role of collagen heterogeneity in remodeling of acute and chronic heart scarsR01HL149687 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEB, ARJUN, PELLEGRINI, MATTEO · 2020 to 2023
$2.0M
Identifying therapeutic strategies for the multisystem genetic disorder Pseudoxanthoma ElasticumR01AR075867 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DEB, ARJUN · 2020 to 2023
$1.4M
British Heart Foundation CH/1996001/9454Medical Research Council MC_PC_17228Medical Research Council MC_QA137853NHLBI NIH HHS R01 HL133169NHLBI NIH HHS R01 HL137241NHLBI NIH HHS R01 HL144651NHLBI NIH HHS R01 HL148110NHLBI NIH HHS R01 HL149658NHLBI NIH HHS R01 HL149687NHLBI NIH HHS R01 HL152176NIAMS NIH HHS R01 AR075867NIDDK NIH HHS R01 DK117850NIDDK NIH HHS R01 DK132735NIEHS NIH HHS R01 ES025786
6 · The paper itself

Abstract

Individuals with features of metabolic syndrome are particularly susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus associated with the severe respiratory disease, coronavirus disease 2019 (COVID-19). Despite considerable attention dedicated to COVID-19, the link between metabolic syndrome and SARS-CoV-2 infection remains unclear. Using data from the UK Biobank, we investigated the relationship between severity of COVID-19 and metabolic syndrome-related serum biomarkers measured prior to SARS-CoV-2 infection. Logistic regression analyses were used to test biomarker levels and biomarker-associated genetic variants with SARS-CoV-2-related outcomes. Among SARS-CoV-2-positive cases and negative controls, a 10 mg/dl increase in serum HDL-cholesterol or apolipoprotein A1 levels was associated with ∼10% reduced risk of SARS-CoV-2 infection, after adjustment for age, sex, obesity, hypertension, type 2 diabetes, and coronary artery disease. Evaluation of known genetic variants for HDL-cholesterol revealed that individuals homozygous for apolipoprotein E4 alleles had ∼2- to 3-fold higher risk of SARS-CoV-2 infection or mortality from COVID-19 compared with apolipoprotein E3 homozygotes, even after adjustment for HDL-cholesterol levels. However, cumulative effects of all evaluated HDL-cholesterol-raising alleles and Mendelian randomization analyses did not reveal association of genetically higher HDL-cholesterol levels with decreased risk of SARS-CoV-2 infection. These results implicate serum HDL-cholesterol and apolipoprotein A1 levels measured prior to SAR-CoV-2 exposure as clinical risk factors for severe COVID-19 infection but do not provide evidence that genetically elevated HDL-cholesterol levels are associated with SAR-CoV-2 infection.

Indexed as

Apolipoprotein A-ICholesterol, HDLCOVID-19HomozygoteMetabolic SyndromeAdultAgedBiomarkersFemaleHumansMaleMiddle AgedPatient AcuitySARS-CoV-2United KingdomApolipoprotein A-IBiomarkersCholesterol, HDLApoE4apolipoprotein A1COVID-19genetic risk scoregenetic variantsHDL-cholesterolMendelian randomizationmetabolic syndromeSAR-CoV-2

Identifiers

PMID33667465
PMCPMC7923911
OpenAlexW3133735962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.